Pilaralisib
Pilaralisib (XL-147) is a selective, orally bioavailable phosphoinositide-3 kinase (PI3K) inhibitor. It has been widely employed in preclinical and clinical research, including in vitro cell-based assays and in vivo xenograft models, to investigate its therapeutic potential in cancers such as breast cancer, lymphoma, and glioblastoma.
Product Specifications
CAS Number
934526-89-3
Product Name Alternative
Inhibitor, inhibit, SAR 245408, SAR245408, SAR-245408, PI3K, Phosphoinositide 3-kinase, XL 147, XL-147, XL147, PI3Kδ, PI3Kβ, PI3Kγ, PI3Kα, Pilaralisib
Field of Research
Signal Transduction
Purity
98.24% (May vary between batches)
Solubility
Ethanol:< 1 mg/mL (insoluble or slightly soluble) ; DMSO:93 mg/mL (171.9 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (6.1 mM)
Smiles
COc1ccc (Cl) c (Nc2nc3ccccc3nc2NS (=O) (=O) c2cccc (NC (=O) C (C) (C) N) c2) c1
Molecular Formula
C25H25ClN6O4S
Molecular Weight
541.02
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Explore Other Products
Browse additional items from our catalog
Recombinant Human Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) (Active)
Recombinant Human Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) (Active)
Recombinant Human Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) (Active)
GNG2 (Guanine Nucleotide-binding Protein G (I) /G (S) /G (O) Subunit gamma-2, G gamma-I)
